NCT05260658View on ClinicalTrials.gov

Safety and Tolerability of CFTX-1554 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

97

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

February 10, 2023

Study Completion Date

February 10, 2023

Conditions

Healthy

Interventions

DRUG

CFTX-1554

CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).

DRUG

Placebo

CFTX-1554 matching placebo

Trial Locations (1)

9728

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

Confo Therapeutics

All Listed Sponsors

lead

Confo Therapeutics

INDUSTRY